Abdul K.R. Purba

Dr. Abdul K.R. Purba

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2023 in Journal of Obesity
Verified
Journal Article
Open access
PDF file
RYRatih Yudhani
Ratih Yudhani
YSYulia Sari
Yulia Sari
DNDwi Aris Agung Nugrahaningsih
Dwi Aris Agung Nugrahaningsih
ESEti Nurwening Sholikhah
Eti Nurwening Sholikhah
MRMaftuchah Rochmanti
Maftuchah Rochmanti
MMMustofa Mustofa
Mustofa Mustofa
Insulin resistance, which affects insulin-sensitive tissues, including adipose tissues, skeletal muscle, and the liver, is the central pathophysiological mechanism underlying type 2 diabetes progression. Decreased glucose uptake in insulin-sensitive tissues disrupts insulin signaling pathways, particularly the PI3K/Akt pathway. An in vitro model is appropriate for studying the cellular and molecular mechanisms underlying insulin resistance because it is easy to maintain and the results can be easily reproduced. The application of cell-based models for exploring the pathogenesis of diabetes and insulin resistance as well as for developing drugs for these conditions is well known. However, a comprehensive review of in vitro insulin resistance models is lacking. Therefore, this review was conducted to provide a comprehensive overview and summary of the latest in vitro insulin resistance models, particularly 3T3-L1 (preadipocyte), C2C12 (skeletal muscle), and HepG2 (liver) cell lines induced with palmitic acid, high glucose, or chronic exposure to insulin.

18 July 2018 in Frontiers in Pharmacology
Verified
Journal Article
Open access
APAbdul K.R. Purba
Abdul K.R. Purba
DSDidik Setiawan
Didik Setiawan
EBErik Bathoorn
Erik Bathoorn
MPMaarten J. Postma
Maarten J. Postma
JDJan-Willem H. Dik
Jan-Willem H. Dik
AFAlex W. Friedrich
Alex W. Friedrich
Introduction: The preoperative phase is an important period in which to prevent surgical site infections (SSIs). Prophylactic antibiotic use helps to reduce SSI rates, leading to reductions in hospitalization time and cost. In clinical practice, besides effectiveness and safety, the selection of prophylactic antibiotic agents should also consider the evidence with regard to costs and microbiological results. This review assessed the current research related to the use of antibiotics for SSI prophylaxis from an economic perspective and the underlying epidemiology of microbiological findings. Methods: A literature search was carried out through PubMed and Embase databases from 1 January 2006 to 31 August 2017. The relevant studies which reported the use of prophylactic antibiotics, SSI rates and costs were included for analysis. The causing pathogens for SSIs were categorized by sites of the surgery. The quality of reporting on each included study was assessed with the “Consensus on Health Economic Criteria” (CHEC). Results: We identified 20 eligible full-text studies that met our inclusion criteria were subsequently assessed, resulting in a reporting quality scored on the CHEC list averaging 13.03 (8-18.5). Of the included studies, 14 were trial-based studies, and the others were model-based studies. The SSI rates ranged from 0 to 71.1% with costs amounting to US$480-22,130. Twenty-four bacteria were identified as causative agents of SSIs. Gram negatives were the dominant causes of SSIs especially in general surgery, neurosurgery, cardiothoracic surgery and obstetric cesarean sections. Conclusions: Varying results were reported in the studies reviewed. Yet, information from both trial-based and model-based costing studies could be considered in the clinical implementation of proper and efficient use of prophylactic antibiotics to prevent SSIs and antimicrobial resistance. Nevertheless, the findings of economics and microbiology from the included studies have reported diverse results.

23 September 2019 in Quality of Life Research
Verified
Journal Article
Open access
PDF file
BABustanul Arifin
Bustanul Arifin
APAri Probandari
Ari Probandari
APAbdul K.R. Purba
Abdul K.R. Purba
Dyah PerwitasariDyah Perwitasari
Dyah Perwitasari
CSCatharina C. M. Schuiling-Veninga
Catharina C. M. Schuiling-Veninga
MPMaarten J. Postma
Maarten J. Postma
Background: More than two-thirds of patients diagnosed with type 2 diabetes mellitus (T2DM) in Indonesia encounter medical-related problems connected to routine self-management of medication and the social stigma related to T2DM. The current study aims to explore distress and coping strategies in Indonesian T2DM outpatients in a Primary Healthcare Centre (PHC) in Surabaya, East Java, Indonesia. Methods: We conducted a qualitative study using two different data collection methods: focus group discussions and in-depth interviews. The guideline of interviews and discussions were developed based on seventeen questions derived from the DDS17 Bahasa Indonesia (a Bahasa Indonesia version of the Diabetes Distress Scale questionnaire), which covered physician distress domain, emotional burden domain, regimen distress domain and interpersonal distress domain. Results: The majority of the 43 participants were females and aged 50 or older. Our study discovered two main themes: internal and external diabetes distress and coping strategies. Internal diabetes distress consists of disease burden, fatigue due to T2DM, fatigue not due to T2DM, emotional burden (fear, anxiety, etc.) and lack of knowledge. Internal coping strategies comprised spirituality, positive attitude, acceptance and getting more information about T2DM. External diabetes distress was evoked by distress concerning healthcare services, diet, routine medication, monthly blood sugar checks, interpersonal distress (family) and financial concern. External coping strategies included healthcare support, traditional medicine, vigilance, self-management, social and family support and obtaining information about health insurance. Conclusion: Our study shows that for Indonesian T2DM-patients, spirituality and acceptance are the most common coping mechanisms for reducing DD. Furthermore, our study revealed an overall positive attitude towards dealing with T2DM as well as a need for more information about T2DM and potential coping strategies. Finally, an important finding of ours relates to differences in DD between males and females, potential DD associated with health services provision and the specific challenges faced by housewives with T2DM.

1 July 2020 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
APAbdul K.R. Purba
Abdul K.R. Purba
NMNina Mariana
Nina Mariana
GAGestina Aliska
Gestina Aliska
SWSonny Hadi Wijaya
Sonny Hadi Wijaya
RWRiyanti Retno Wulandari
Riyanti Retno Wulandari
MPMaarten J. Postma
Maarten J. Postma
We aimed to determine the burden of sepsis with focal infections in the resource-limited context of Indonesia and to propose national prices for sepsis reimbursement. We conducted a retrospective observational study on cost from 2013-2016 of surviving and non-surviving sepsis patients with payer perspective using inpatient billing records in 4 hospitals. We calculated the national burden of sepsis and developed proposed national prices for reimbursement. Of 14,076 sepsis patients in total, 5,876 (41.7%) survived and 8.200 (58.3%) deceased. The mean hospital costs incurred per surviving and deceased sepsis patient were US$1,011 (SE + 23.4) and US$1,406 (SE + 27.8), respectively. The national burden of sepsis in 100,000 patients was estimated to be US$130 million. Sepsis patients with multifocal infections and a single focal infection of lower-respiratory tract infections (LRTIs) were estimated as the two with the highest economic burden (US$48 million and US$33 million, respectively, within the 100,000 sepsis patients). Sepsis with cardiovascular infection was estimated to warrant the highest proposed national price for reimbursement (US$4,256). Multifocal infections and LRTIs are the major focal infections with the highest burden of sepsis. Our study shows varying cost estimates for sepsis, necessitating a new reimbursement system with adjustment of the national prices taking the particular foci into account.

1 November 2019 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
APAbdul K.R. Purba
Abdul K.R. Purba
PAPurwantyastuti Ascobat
Purwantyastuti Ascobat
AMArmen Muchtar
Armen Muchtar
LWLaksmi Wulandari
Laksmi Wulandari
ARAlfian Nur Nur Rosyid
Alfian Nur Nur Rosyid
MPMaarten J Postma
Maarten J Postma
Objectives: To evaluate the clinical and microbiological appearance among hospitalized pneumonia patients focusing on resistance and risk factors for mortality in a referral hospital. Patients and methods: The study was an observational retrospective study on patients with CAP from 2014 to 2016 at Dr Soetomo referral hospital of Surabaya, Indonesia. All positive cultures with antimicrobial susceptibility results from blood and respiratory specimens were included. Patients infected with drug-susceptible pathogens and MDR organisms were also assessed in terms of clinical characteristics, day-3 clinical improvement, and 14-day mortality. Results: Of 202 isolates, 181 possessed antimicrobial susceptibility data. S. pneumoniae was the most prevalent pathogen causing CAP (18.3%). Most patients were empirically treated with ceftriaxone (n=75; 41.4%). Among beta-lactam antibiotics, the susceptibility to the third-generation cephalosporins remained relatively high, between 67.4% and 82.3%, compared with the other beta-lactams such as amoxicillin/clavulanate and ampicillin/sulbactam (a sensitivity rate of 36.5% and 47.5, respectively). For carbapenem antibiotics, imipenem and meropenem susceptibility was 69.6% and 82.3% respectively. Approximately 22% of isolates were identified as MDR that showed significant differences in clinical outcomes of 14-day mortality rates (p<0.001). Notably, patients with day-3 improvement had a lower risk of mortality (OR= 0.06; 95% CI= 0.02–0.19). Conclusion: One-fifth of causative agents among hospitalized CAP cases were identified as MDR organisms. The pathogens of MDR and non-MDR CAP remain susceptible to the third-generation cephalosporins. Together with additional consideration of culture findings and Pneumonia Severity Index (PSI) assessment, a 3-day clinical assessment is essential to predict the prognosis of 14-day mortality.

20 May 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
DLDr.Yasmeen Lashari
Dr.Yasmeen Lashari
MRMaftuchah Rochmanti
Maftuchah Rochmanti
APAbdul K.R. Purba
Abdul K.R. Purba
HNHari Basuki Notobroto
Hari Basuki Notobroto
RSrosantia sarassari
rosantia sarassari
KKKuntaman Kuntaman
Kuntaman Kuntaman
Background: Carbapenem resistant-non lactose fermenter (CR-NLF) and Carbapenem resistant-Enterobacteriaceae (CR-E) bacterial infections are likely to be a global threat to people’s health. However, studies on the economic impacts according to the hospital setting are very scarce. The study aimed to explore the impact of CR-NLF (Acinetobacter baumannii = CRAB) & Pseudomonas aeruginosa = CRPA) and CR-E (Escherichia coli = CREC) & Klebsiella pneumoniae = CRKP) infections on hospital costs from a payer perspective among patients admitted to Dr.Soetomo Hospital, Surabaya, Indonesia. Methods: In the retrospective case-control study, medical records of all included patients hospitalized during 2018–2021 were reviewed for CRAB, CRPA, CREC, CRKP, and carbapenem sensitive (CSAB, CSPA, CSEC, CSKP) were collected. We retrieved the data of age, gender, clinical specimen, dates of admission, and discharge status. The outcomes of interest were hospital length of stay and hospitalization cost. Results: The cost for CR-NLFs infections was higher than carbapenem sensitive, $3026.24 versus $1299.28 (p < 0.05). There was no significant difference between CR-E against carbapenem sensitive. It showed that the highest impact of the cost was CRAB, followed by CRPA, CRKP, and CREC. The bed, antibiotics, pharmacy, and diagnostic costs of CR-NLFIs were significantly higher than CR-E. Conclusion: This study showed that the hospital cost and expenditure of CR-NLFs per patient were higher than CS. The hospital cost per patient for CR-NLF was higher than CR-E.